Cash cost of the wait: management is funding a defined waiting period whose end is already scheduled
The model's full reasoning — Q3 2018 call → NOWe need to answer YES or NO based on the transcript. The question asks: Does management describe the company as currently living through a defined waiting period it is paying for out of its own pocket? That is, does management convey that the company is presently carrying real, ongoing cash or earnings cost for something whose benefit has not arrived yet, AND that the end of that waiting period is a specific, near-dated event the company can already see and is already working toward? We need to find in the transcript a situation where the company is paying now for something not yet earning, management speaks as though the wait is the main current work, and the far side is a specific near-dated event. Let's review the transcript. The company is Agios Pharmaceuticals. They have products: TIBSOVO (ivosidenib) launched in July 2018, and IDHIFA (enasidenib) partnered with Celgene. They have clinical programs. Key points: They launched TIBSOVO in July 2018, and they report net sales of $4.5 million for the third quarter. So they are already earning from TIBSOVO. They also have IDHIFA royalties. So they have revenue. But the question is about a defined waiting period where they are paying for something not yet earning. Could be about their clinical trials? Or about manufacturing? Or about a new indication? Or about a new drug launch? Let's look for any mention of costs being incurred for something that hasn't started yet, with a near-dated event. In the transcript, they discuss the sNDA for TIBSOVO in newly diagnosed AML patients not eligible for standard therapies. They plan to submit by end of January 2019. That is a regulatory submission, not a cost-bearing waiting period. They also discuss the Phase 3 AGILE trial, which they are revising to reduce patient numbers, and expect to complete enrollment in 2020. That's not near-dated. They discuss AG-270, a MAT2A inhibitor in Phase 1 dose-escalation. They are seeing expected pharmacodynamic effects. No mention of a waiting period. They discuss Mitapivat in pyruvate kinase deficiency, expecting to complete enrollment in 2019. That's a clinical trial, not a cost-bearing waiting period in the sense of paying for something not yet earning? Actually, clinical trials are costs, but they are investments in future products.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| SBS | Companhia de Saneamento Básico do Estado | Q3 2023 | 2023-11-10 | C+ |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| YUM | Yum! Brands, Inc. | Q2 2018 | 2018-08-02 | C |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
SBS · Q3 2023 → YESThe question is whether management describes the company as currently living through a defined waiting period it's paying for out of its own pocket. YES The transcript shows management describing the company as currently bearing real, ongoing cash costs (salaries, consulting, transition work) for the IDP/restructuring program whose benefits (full expense reduction, shared-services center operational) are not yet realized. The far side is a specific, near-dated event: full 3.7% staff reduction and shared-services center operational by mid-2024 (July 2024 for full benefit), with the program already in motion and on schedule. Management frames this as the main current work, not a setback, and treats the costs as self-funded. This meets all three conditions.
EHTH · Q2 2021 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing the company as currently living through a defined waiting period for the AEP, paying for it out of its own pocket through heavy investments in internal agents and quality initiatives. They hired agents early, many still in training with lower productivity, and are bearing the cost of additional training and customer service expansion in Q3. This is framed as a chosen investment to improve enrollment quality and prepare for the fourth-quarter AEP, not an apology or external issue.
YUM · Q2 2018 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing a clear, self-funded transition cost tied to the refranchising effort. They explicitly call out the “timing mismatch between G&A savings and refranchising” as one of the four items weighing on Q2 core operating profit, and they quantify the full-year headwind at 6 7 percentage points. This is presented as a real, ongoing drag on current results while they complete the shift to 98 % franchised by year-end 2018 and reach the 1.7 % G&A run-rate target in 2019.